Caribou Biosciences Teases vispa-cel Phase 3 LBCL Plan, Eyes Financing at Leerink Conference

March 14, 2026 - 21:48

At the Leerink Global Healthcare Conference, executives from Caribou Biosciences detailed a strategic roadmap for the coming year, centering on the advancement of their primary investigational therapy, vispa-cel. The allogeneic cell therapy candidate is poised to enter a pivotal Phase 3 trial for patients with relapsed or refractory large B-cell lymphoma (LBCL) who have undergone at least two prior lines of therapy.

Company leadership indicated that final study design is being solidified in consultation with the U.S. Food and Drug Administration, with the trial expected to initiate in the second half of 2024. This late-stage study represents a critical step in demonstrating the therapy's potential as an "off-the-shelf" alternative to personalized cell treatments.

Alongside these clinical ambitions, the company openly addressed its financial strategy. Management confirmed active efforts to secure additional capital, necessary to fund the expensive Phase 3 trial and further pipeline development. The need for financing is a common theme for biotech firms progressing assets into large, definitive studies.

Beyond vispa-cel, Caribou highlighted its broader pipeline, including earlier-stage programs targeting autoimmune diseases. The presentation underscored a period of significant operational execution ahead, as the company works to translate its CRISPR-based cell therapy platform into late-stage clinical data and, ultimately, a commercially available product for patients.